How To Use CPT Code 0105U

CPT 0105U describes the multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD). This article will cover the description, procedure, qualifying circumstances, appropriate usage, documentation requirements, billing guidelines, historical information, and examples.

1. What is CPT Code 0105U?

CPT 0105U can be used to describe the KidneyIntelX™ test from RenalytixAI. This test combines the results of an immunoassay procedure to detect tumor necrosis factors and kidney injury molecule-1 with clinical data in an algorithm. The test provides a score that predicts the probability of rapid decline in kidney function in a patient.

2. Official Description

The official description of CPT code 0105U is: ‘Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD).’

3. Procedure

1. The lab analyst performs a multiplex electrochemiluminescent immunoassay (ECLIA) test on a plasma specimen.
2. The test detects and measures tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) using immunoassay methods.
3. The results of the immunoassay are combined with longitudinal clinical data, including APOL1 genotype if available, into an algorithm.
4. The algorithm provides a score that predicts the probability of rapid decline in kidney function (RKFD) in a patient.

4. Qualifying circumstances

CPT 0105U is used for patients with type 2 diabetes who appear to have rapidly progressive kidney disease. The test is ordered to develop a treatment plan to slow down, curtail, and prevent further progression. It is important to note that this test is specific to the KidneyIntelX™ test from RenalytixAI and should not be used for other purposes.

5. When to use CPT code 0105U

CPT code 0105U should be used when ordering the KidneyIntelX™ test from RenalytixAI for patients with type 2 diabetes who show signs of rapidly progressive kidney disease. It should not be used for any other tests or purposes.

6. Documentation requirements

To support a claim for CPT code 0105U, the documentation should include:

• Order for the KidneyIntelX™ test from RenalytixAI
• Results of the multiplex electrochemiluminescent immunoassay (ECLIA) test
• Longitudinal clinical data, including APOL1 genotype if available
• Algorithm-generated probability score for rapid kidney function decline (RKFD)

7. Billing guidelines

When billing for CPT code 0105U, ensure that the test is performed by RenalytixAI for the KidneyIntelX™ test. Report one unit of this code for a single specimen analyzed on a single date of service. It is important to check with the appropriate payer regarding payment for specimen collection. Do not report this test with any other CPT code.

8. Historical information

CPT code 0105U was added to the Current Procedural Terminology system on October 1, 2019. There have been no updates to the code since its addition.

9. Examples

1. A patient with type 2 diabetes showing signs of rapidly progressive kidney disease undergoes the KidneyIntelX™ test from RenalytixAI to determine the probability of rapid kidney function decline.
2. A clinician orders the KidneyIntelX™ test from RenalytixAI for a patient with type 2 diabetes who has a family history of kidney disease and wants to assess their risk of rapid kidney function decline.
3. A patient with type 2 diabetes and elevated levels of tumor necrosis factors undergoes the KidneyIntelX™ test from RenalytixAI to evaluate their probability of rapid kidney function decline.
4. A clinician orders the KidneyIntelX™ test from RenalytixAI for a patient with type 2 diabetes who has experienced a sudden decline in kidney function to assess the likelihood of further decline.
5. A patient with type 2 diabetes and known APOL1 genotype undergoes the KidneyIntelX™ test from RenalytixAI to determine their probability of rapid kidney function decline.
6. A clinician orders the KidneyIntelX™ test from RenalytixAI for a patient with type 2 diabetes who has been experiencing symptoms of kidney disease to assess their risk of rapid kidney function decline.
7. A patient with type 2 diabetes and a history of rapid kidney function decline undergoes the KidneyIntelX™ test from RenalytixAI to monitor their current kidney function and assess the likelihood of further decline.
8. A clinician orders the KidneyIntelX™ test from RenalytixAI for a patient with type 2 diabetes who is considering treatment options for kidney disease and wants to evaluate their risk of rapid kidney function decline.
9. A patient with type 2 diabetes and elevated levels of kidney injury molecule-1 undergoes the KidneyIntelX™ test from RenalytixAI to determine their probability of rapid kidney function decline.
10. A clinician orders the KidneyIntelX™ test from RenalytixAI for a patient with type 2 diabetes who has been experiencing frequent urinary tract infections to assess their risk of rapid kidney function decline.